Cure My Disease

Don't miss your cure!

 Log in / Sign up

A common mineral may boost pain relief after breast cancer surgery

NCT ID NCT07789600

Symptom relief Sponsor: King Hussein Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Sep 01, 2026 · Updated 3 times

Summary

This trial tests whether adding magnesium sulfate to a standard local anesthetic, bupivacaine, can improve pain control after a mastectomy with lymph node removal. About 70 adult women undergoing this surgery will receive either the magnesium combination or the standard anesthetic alone, injected into the wound during the operation. Researchers will measure pain levels and painkiller use over the first 24 hours, with a follow-up safety check one to two weeks later. The goal is to see if this simple addition can reduce postoperative pain and the need for stronger pain medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnesium sulfate added to bupivacaine for local wound infiltration
What this could lead to
If it works, this could offer a simple, safe way to ease pain after mastectomy and reduce the need for opioid painkillers.
What could go wrong
This is a small, early-stage trial, and the benefit may be modest. Magnesium can cause side effects like low blood pressure or nausea, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult female patients (age ≥18 years) undergoing elective modified radical mastectomy (MRM) with axillary clearance. * ASA physical status I-III. * Willingness to participate and provide informed consent. Exclusion Criteria: * Allergy to bupivacaine or magnesium. * Chronic opioid use or pre-existing chronic pain conditions. * Significant renal or hepatic impairment. * Pregnancy or lactation. * Neuromuscular disorders. * Abnormal baseline serum magnesium levels (e.g., hypermagnesemia).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Modified radical mastectomy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Modified radical mastectomy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King Hussien Cancer Centre

    Amman, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.